Narrow search
Showing 1 - 10 of 48
Cover Image
Have Newer Cardiovascular Drugs Reduced Hospitalization? Evidence from Longitudinal Country-Level Data on 20 OECD Countries, 1995-2003
Lichtenberg, Frank R. - 2010
This study examines the effect of changes in the vintage distribution of cardiovascular system drugs on hospitalization and mortality due to cardiovascular disease using longitudinal country-level data. The vintage of a drug is the first year in which it was marketed anywhere in the world. We...
Persistent link: https://www.econbiz.de/10012759312
Cover Image
Have Newer Cardiovascular Drugs Reduced Hospitalization? Evidence From Longitudinal Country-Level Data on 20 OECD Countries, 1995-2003
Lichtenberg, Frank R. - 2008
Countries with larger increases in the share of cardiovascular drug doses that contained post-1990 or post-1995 ingredients had smaller increases in the cardiovascular disease hospital discharge rate, controlling for the quantity of cardiovascular medications consumed per person, the use of...
Persistent link: https://www.econbiz.de/10012464639
Cover Image
The impact of pharmaceutical innovation on cancer mortality in Mexico, 2003-2013
Lichtenberg, Frank R. - In: Latin American Economic Review 26 (2017) 1, pp. 1-22
I assess the impact that pharmaceutical innovation had on cancer mortality in Mexico during the period 2003-2013, by ….) that were subject to more pharmaceutical innovation, controlling for changes in the age-standardized cancer incidence rate … of cancer drug innovation to Mexican longevity growth has been valuable, but, perhaps, it could have been even larger …
Persistent link: https://www.econbiz.de/10011994326
Cover Image
The association between pharmaceutical innovation and both premature mortality and hospital utilization in Switzerland, 1996-2019
Lichtenberg, Frank R. - In: Swiss Journal of Economics and Statistics 158 (2022) 1, pp. 1-24
We analyze the association that pharmaceutical innovation had with premature mortality from all diseases in Switzerland … 2002-2019. The analysis is performed by investigating whether the diseases that experienced more pharmaceutical innovation … had larger subsequent declines in premature mortality and hospitalization. Pharmaceutical innovation is measured by the …
Persistent link: https://www.econbiz.de/10013205824
Cover Image
Are patients more adherent to newer drugs?
Blankart, Katharina E.; Lichtenberg, Frank R. - In: Health Care Management Science 23 (2020) 4, pp. 605-618
The annual preventable cost from non-adherence in the US health care system amounts to $100 billion. While the relationship between adherence and the health system, the condition, patient characteristics and socioeconomic factors are established, the role of the heterogeneous productivity of...
Persistent link: https://www.econbiz.de/10014503918
Cover Image
Spurious correlation in estimation of the health production function: A note
Akkoyunlu, Sule; Lichtenberg, Frank R.; Siliverstovs, Boriss - 2009
contribution by Lichtenberg (2004), which relates longevity in the United States to pharmaceutical innovation and public health …
Persistent link: https://www.econbiz.de/10010315553
Cover Image
Spurious correlation in estimation of the health production function: A note
Akkoyunlu, Sule; Lichtenberg, Frank R.; Siliverstovs, Boriss - 2009
contribution by Lichtenberg (2004), which relates longevity in the United States to pharmaceutical innovation and public health …
Persistent link: https://www.econbiz.de/10010285825
Cover Image
Have newer cardiovascular drugs reduced hospitalization? : Evidence from longitudinal country-level data on 20 OECD countries, 1995 - 2003
Lichtenberg, Frank R. - 2008
"This study examines the effect of changes in the vintage distribution of cardiovascular system drugs on hospitalization and mortality due to cardiovascular disease using longitudinal country-level data. The vintage of a drug is the first year in which it was marketed anywhere in the world. We...
Persistent link: https://www.econbiz.de/10003716085
Cover Image
Response to Baker and Fugh-Berman's critique of my paper, "Why has longevity increased more in some states than in others?"
Lichtenberg, Frank R. - 2009
innovation accounts for a substantial portion of recent increases in U.S. life expectancy. Baker and Fugh-Berman claim that my … literature. Baker and Fugh-Berman express deep skepticism about my study's conclusion that medical innovation has played a very …
Persistent link: https://www.econbiz.de/10003861794